Surrozen (SRZN) Interest Expenses (2020 - 2026)
Surrozen (SRZN) posted quarterly Interest Expenses of $23.0 million for Q1 2026, up 350.16% year-over-year from $5.1 million in Q1 2025, and up 919.93% quarter-over-quarter from -$2.8 million in Q4 2025.
Surrozen (SRZN) Interest Expenses (2020 - 2026) Analysis & Trends
Surrozen's Interest Expenses history runs 7 years deep, the most recent figure standing at $23.0 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 350.16% year-over-year to $23.0 million; the TTM figure through Mar 2026 stood at $23.0 million (up 350.16% YoY), while the FY2025 annual figure was $12.9 million, down 75.22% from the prior year.
- Interest Expenses for Q1 2026 stood at $23.0 million, up from -$2.8 million in the prior quarter.
- The five-year high for Interest Expenses was $51.9 million in Q4 2024, with the low at -$2.8 million in Q4 2025.
- The 5-year median for Interest Expenses is $5.1 million (2025), against an average of $8.1 million.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 864833.33% in 2024, then plunged 105.4% in 2025.
- Surrozen's Interest Expenses stood at $3000.0 in 2022, then surged by 100.0% to $6000.0 in 2023, then surged by 864833.33% to $51.9 million in 2024, then slumped by 105.4% to -$2.8 million in 2025, then jumped by 919.93% to $23.0 million in 2026.
- Business Quant data shows SRZN's Interest Expenses at $23.0 million in Q1 2026, -$2.8 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 17.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.09 Mn |
| Jun 30, 2026 | 17.09 Mn |
| Mar 31, 2026 | 22.96 Mn |
| Mar 31, 2026 | 22.96 Mn |
| Dec 31, 2025 | -2.80 Mn |
| Dec 31, 2025 | -2.80 Mn |
| Sep 30, 2025 | 8.24 Mn |
| Sep 30, 2025 | 8.24 Mn |
| Jun 30, 2025 | 8.82 Mn |
| Jun 30, 2025 | 8.82 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 51.90 Mn |
| Dec 31, 2024 | 51.90 Mn |
| Sep 30, 2024 | 1.56 Mn |
| Sep 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 2.24 Mn |
| Mar 31, 2024 | 2.91 Mn |
| Mar 31, 2024 | 2.91 Mn |